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Abstract: Primary Ciliary Dyskinesia (PCD) is a rare, under-recognized disease that affects respiratory
ciliary function, resulting in chronic oto-sino-pulmonary disease. The PCD clinical phenotype
overlaps with other common respiratory conditions and no single diagnostic test detects all forms of
PCD. In 2018, PCD experts collaborated with the American Thoracic Society (ATS) to create a clinical
diagnostic guideline for patients across North America, specifically considering the local resources
and limitations for PCD diagnosis in the United States and Canada. Nasal nitric oxide (nNO) testing
is recommended for first-line testing in patients ≥5 years old with a compatible clinical phenotype;
however, all low nNO values require confirmation with genetic testing or ciliary electron micrograph
(EM) analysis. Furthermore, these guidelines recognize that not all North American patients have
access to nNO testing and isolated genetic testing is appropriate in cases with strong clinical PCD
phenotypes. For unresolved diagnostic cases, referral to a PCD Foundation accredited center is
recommended. The purpose of this narrative review is to provide insight on the North American
PCD diagnostic process, to enhance the understanding of and adherence to current guidelines, and
to promote collaboration with diagnostic pathways used outside of North America.
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Primary ciliary dyskinesia (PCD) is a rare disease with an estimated prevalence of 1 in
15,000 individuals [1,2]. Despite improved understanding of the clinical phenotype, PCD
remains under-recognized. The PCD Foundation (PCDF) estimates that only about 10% of
people with PCD have been definitively diagnosed and followed at a PCD clinical center.
This discrepancy is likely due to low disease recognition by clinical providers and limited
access to specialized diagnostic services in many clinical centers across the US and Canada.
In 2018, a panel of experts, sponsored by the American Thoracic Society (ATS), published a PCD diagnostic pathway focused on techniques most readily available in the US
and Canada [3]. While these guidelines recognize the utility of highly specialized centers
of excellence, accredited in the PCDF Clinical and Research Center Network (CRCN),
they also consider a comprehensive approach for clinicians who are not a part of the
PCDF CRCN.
In 2017, the European Respiratory Society (ERS) also published guidelines based
on pre-defined questions relevant for the diagnosis and clinical care of PCD patients [4].
Differences in the ATS and ERS guidelines have previously been highlighted [5] and reflect
the differences in diagnostic testing available in North America and Europe.
The ATS Clinical Practice Guideline for diagnosing PCD recommends that, when
possible, appropriate patients with a compatible clinical PCD phenotype first undergo nasal
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nitric oxide (nNO) measurement, as an easy and well-established tool for PCD screening.
Individuals with low nNO values can then be further evaluated using confirmatory PCD
tests, including extended panel genetic testing or ciliary ultrastructural evaluation by
transmission electron microscopy (TEM). The guideline also recognizes that nNO testing
may not be readily available or feasible when patients are young (and thus uncooperative).
In these cases, extended panel genetic testing is recommended as the first-line test for PCD
diagnosis. Notably, some PCD testing modalities used outside of North America, including
ciliary beat pattern analysis by high speed videomicroscopy, [6] was not adopted by the
ATS guidelines.
In addition to guideline recommendations, we briefly present the evolving network
of PCD specialty centers being established across the US and Canada through the PCDF
CRCN. Through a standardized accreditation process, participating centers adhere to
common benchmarks for PCD diagnosis and therapies [7], while also participating in a
PCD Foundation clinical patient registry, which will eventually aid with PCD clinical trials
across North American centers.
2. Recognition of the Clinical Phenotype
PCD is a disease of impaired motor cilia function associated with a growing list of
causative genes. Most pediatric PCD patients exhibit several key clinical features including:
(a) persistent, year-round wet cough that starts in the first year of life, (b) persistent,
year-round nasal congestion that also starts in the first year of life, (c) the presence of
organ laterality abnormalities, and (d) unexplained neonatal respiratory distress in infants
born at term gestation [8]. While PCD patients often display otitis media with persistent
effusion, chronic bronchitis, and recurrent pneumonia, these issues are prevalent in many
other children presenting for respiratory care and thus do not readily assist physicians
in discerning which patients should undergo further PCD investigations. However, the
complete absence of middle ear disease or recurrent lower respiratory tract infections
makes PCD less likely. The ATS PCD diagnostic guidelines recommend that at least two of
the key clinical PCD features be present for the pre-test probability to be high enough to
proceed with PCD diagnostic testing [3,8].
Unlike other overlapping pediatric respiratory conditions, PCD usually presents
with persistent symptoms on a daily, non-seasonal basis; the symptoms never completely
resolve, even with prolonged antibiotic courses. The persistent wet cough and rhinorrhea
often appear before 6 months of age, though many families report onset at birth. Neonatal
respiratory distress, despite term birth, is seen in at least 80% of PCD cases and can
have a delayed onset (median onset at 12 h of life, with a range of 0 to 72 h of life),
accompanied by lobar atelectasis on chest radiography [9]. The duration of neonatal
respiratory distress in PCD is often prolonged, with a median of 14 days [8,9], and some
cases require supplemental oxygen therapy for several months.
In adult PCD populations, persistent wet cough and nasal congestion on a daily basis
remain key clinical features, though the age of symptom onset and presence of neonatal
respiratory distress are often forgotten in these cases [10]. Chronic sinusitis with polyposis
and male infertility, as well as female subfertility, are also frequently reported by adults
with PCD; additionally, bronchiectasis is universally present in the adult PCD populations.
Organ laterality defects are also common in PCD, due to the motility defects of the
embryonic monocilia, which appear during early embryogenesis. However, organ laterality
defects only occur in 50% of individuals with PCD and can result in a variety of organ
arrangements, including situs inversus totalis (mirror image organ arrangement), situs ambiguus (a mix or left-right organ arrangement, often with congenital heart defects), isolated
organ laterality defects (such as dextrocardia), polysplenia, interrupted inferior vena cava,
and others [11] (Figure 1). When situs ambiguus occurs with complex congenital heart
lesions, the label “heterotaxy” is often used, though situs ambiguus organ arrangements
can similarly occur with mild congenital heart defects (such as ventricular septal defects).
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Cross-sectional and longitudinal observations have shown that ≥90% of individuals
with PCD have nasal NO levels below 77 nL/min [18], when measured per a standardized
protocol. Pooled sensitivity and specificity estimates for nNO < 77 nL/min are 96% and
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96%, respectively, in cases of PCD that were confirmed using TEM and/or genetic analysis
and when cystic fibrosis has been ruled out [23]. Low nasal NO values should be confirmed
with at least one additional test on a separate visit, with patients at their baseline health,
and without evidence of viral respiratory infection.
Around 5–10% of PCD cases have nNO values above the established cut-off of 77
nL/min, specifically those associated with mutations in radial spoke or central apparatus
proteins [23,24]. These include cases due to genetic variants in RSPH1, which are associated
with normal ciliary ultrastructure by TEM and nNO values of 100 to 300 nL/min [18]
(Table 1).
Table 1. PCD genotypes grouped by reported nasal nitric oxide (nNO) values. Reported case numbers of specific genes
with nNO > 77nl/min are presented in parentheses.
nNO Routinely ≤ 77 nL/min

Limited Cases with nNO > 77 nL/min

nNO Routinely > 77 nL/min

ARMC4

DNAI2

DNAH9 (9 cases) [25,26]

CCDC103 [27]

CCDC39

DNAJB13

TTC12 (2 cases) [28]

RSPH1 [29]

CCDC40

DNAL1

RPGR (<10 cases) [30,31]

CCDC114

DRC1

CCNO (2 cases) [32]

CCDC151

DRC2

FOXJ1 (4 cases) [33]

CFAP57

HYDIN

NEK10 (1 case) [34,35]

CFAP298

LRRC6

GAS2L2 (2 cases) [36]

CFAP300

MCIDAS

GAS8 (1 cases) [37]

DNAAF1

NME5

STK36 (1 case) [38]

DNAAF2

NME8

CFAP221 (3 cases) [39]

DNAAF3

OFD1

SPEF2 (1 cases) [40–42]

DNAAF4

PIHID3

LRRC56 (1 case) [43]

DNAAF5

RSPH3

DNAH1

RSPH4A

DNAH5

RSPH9

DNAH8

SPAG1

DNAH11

TTC25

DNAI1

ZMYND10

Successful nNO testing requires a patient be cooperative enough to blow into a resistor
device and achieve steady state NO measurement. Children under 5 years old often cannot
perform this maneuver, so nNO testing may not be appropriate in preschool-aged children.
Tidal breathing nNO measurements for patients 2–5 years old are feasible and are currently
under investigation; however, diagnostic cut-off values are undefined in this age group.
According to ATS guidelines, in patients with an appropriate PCD clinical phenotype
and one nNO value <77 nL/min, a repeat measurement is recommended at least 2 weeks
later [44]. With repeat low nNO values and negative cystic fibrosis testing, a presumptive
diagnosis of PCD can be made and appropriate PCD therapies commenced. However, the
availability of nNO testing is still hampered by the lack of clinical regulatory approval in
North America; thus, most nNO tests are performed under research protocols in certified
PCD centers, which are not reimbursed by insurance plans.
3.2. PCD Genetic Testing
PCD is a genetically heterogenous disease caused by variants of more than 50 genes.
This number will probably increase as more gene mutations are associated with PCD.
The most frequently reported mutations occur in DNAI1 and DNAH5, which were the
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Although the increased availability of genetic tools is transformative for PCD diagAlthough the increased availability of genetic tools is transformative for PCD diagnosis, interpreting the results of these tests may be challenging, due to the high number
nosis, interpreting the results of these tests may be challenging, due to the high number
of variants of unknown significance (VUS), which often occur when there is discrepancy
of variants of unknown significance (VUS), which often occur when there is discrepancy
in the prediction tools used to determine pathogencity or when mutations were not prein the prediction tools used to determine pathogencity or when mutations were not previously reported to be pathogenic. PCD diagnosis requires two pathogenic variants be
viously reported to be pathogenic. PCD diagnosis requires two pathogenic variants be
found in a single known PCD gene, on two opposite chromosomes (in trans) or on one
found in a single known PCD gene, on two opposite chromosomes (in trans) or on one
allele, in the case of x-linked or autosomal dominant forms (PIH1D3, RPGR, OFD1, or
FOXJ1). Pathogenicity of VUS results should be evaluated on a case-by-case basis, after
consultation with either a geneticist or a PCD specialty center; VUS results cannot be
assumed as disease-causing for diagnostic purposes.
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3.3. Cilia Ultrastructure Evaluation
Traditionally, the use of TEM to analyze ciliary ultrastructure was considered the
gold standard for a diagnosis of PCD. Motile ciliary cross sections show a typical 9 + 2
arrangement (Figure 2) that represents 9 outer microtubule doublets surrounding a central
pair. Outer dynein arms (ODA) and inner dynein arms (IDA) extend from the microtubule,
acting as the motors powering ciliary movement. [52]. Radial spokes and nexin links
provide stability to beating ciliary axonemes.
Procuring and processing TEM samples requires significant expertise. From sample
collection considerations (i.e., nasal versus endobronchial scraping as opposed to “pinch”
tracheal biopsies) to sample processing considerations (i.e., choice of fixatives and skill of
technicians in choosing multiple ciliary tufts across the sample) the TEM image quality can
vary greatly. Interpretation is similarly challenging and requires evaluation by pathologists
with extensive experience examining ciliary ultrastructure. To address these challenges,
a more recent international consensus guideline focused on reporting TEM results in the
diagnosis of PCD, which included minimal criteria for acceptable TEM studies and the
creation of various diagnostic classes of TEM defects. Per this protocol, only “hallmark”
defects (class 1: absent ODA, absent ODA+IDA, and absent IDA with microtubular disorganization) are reliably diagnostic of PCD [53]. Ultimately, 30% of genetically proven
cases of PCD do not have a hallmark defect on TEM [1], due to the limited sensitivity of
EM in identifying small structural changes in the electron dense ciliary axoneme. This is
especially true when identifying changes affecting the central pair, radial spokes, or inner
dynein arms [54].
A promising diagnostic test using immunofluorescent-labeled antibody microscopy
has been adopted in some European PCD centers [55]. Immunofluorescent antibody
microscopy has the advantage of being more readily available than TEM, costing less per
sample, and is possibly more sensitive than TEM depending on the panel of antibodies
used. However, the diagnostic accuracy of immunofluorescent antibody testing has not
been firmly established in PCD [55]. Most local pathology laboratories also possess the
technical knowledge to process and interpret immunofluorescence antibody samples,
as this technique is currently used in a variety of human diseases. Immunofluorescent
antibody microscopy is currently not available for clinical use in North American centers,
though this technique is being considered at several centers.
3.4. Ciliary Motility and Highspeed Video Microscopy
Mutations associated with PCD often result in changes to ciliary beat frequency
and waveform. The use of a high-speed video microscopy (HSVA) recording for ciliary
waveform analysis is a validated PCD diagnostic tool, which is mostly available in large
European centers [4]. Investigations have shown high sensitivity and specificity for HSVA,
compared to ultrastructural defects on TEM, when performed by specialty centers with
extensive experience in this testing modality [56]. HSVA results should be confirmed by
repeat analyses on several occasions or on cultured ciliated airway cells, which requires
expertise that may not be available in some centers. Further research is needed to compare
the diagnostic accuracy of HSVA against PCD cases with rare genetic causes, as subtle
waveform changes may not be easily detected by HSVA [4,57].
HSVA testing has not gained widespread adoption by PCD centers in North America,
outside of limited research settings [58]. Similar to nNO testing, a normal cilia waveform
analysis does not preclude a diagnosis of PCD, as some mutations may result in normal or
near-normal movement [58]. The use of standard light microscopy for the calculation of
ciliary beat frequency or waveform analysis, without high-speed video recording, is not an
acceptable method to either diagnose or rule out PCD and should be avoided. Future standardization of HSVA practices, including training in image capture and the advancement of
automated or semi-automated analysis algorithms, may allow increased use of high-speed
video microscopy analysis as a diagnostic tool for PCD in North American centers.
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PCD = primary ciliary dyskinesia; TEM = transmission electron microscopy. Reprinted with permission Ref. [24]. Copyright
© 2021 American Thoracic Society.

A central focus of the ATS recommendations is careful recognition of the clinical
phenotype, specifically focusing on the clinical features in the patient history that can help
distinguish those individuals more likely to have PCD from other respiratory conditions.
In starting with phenotype recognition, the ATS guidelines promote the active participation
of clinicians in the diagnosis of PCD, recognizing that it is possible to make a diagnosis
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of PCD through the astute recognition of clinical symptoms and careful interpretation of
genetic results. While genetic testing is widely available at most medical centers in the US
and Canada, this testing is not always available outside of North America, mainly due to
cost and access issues. However, genetic testing samples can be easily obtained through
blood, saliva, or buccal samples; thus, the ATS guidelines present a pathway for improved
PCD diagnosis in middle- and low-income countries, if improved access to genetic testing
is provided.
The ATS guidelines also recognize the benefits of a network of accredited PCD diagnostic centers with expertise in specialized testing. While nNO testing still requires access
to a chemiluminescence analyzer, these are becoming more widespread through the efforts
of the PCD Foundation to expand the number of accredited centers in the PCDF CRCN.
In addition, published technical guidelines for standardized nNO testing now exist [44],
which adds uniformity to the test results that are completed at centers throughout the
US and Canada. Challenges with ciliary TEM reliability and feasibility do exist in North
American academic centers [59], despite this testing modality being well established in
pathology laboratories and used for a multitude of other diseases. While efforts are ongoing to address challenges with the testing, the ATS guidelines recommend TEM analysis
as a second-line test when genetics are inconclusive. This represents a departure from
previous European Respiratory Society recommendations [5,60], though recent advances
in cryo-electron tomography show promise for ultra-high resolution ciliary images, which
may be incorporated into future clinical diagnostic testing [61].
In conclusion, while the focus of the ATS guidelines was the US and Canada, many of
the diagnostic challenges described in this manuscript exist in other areas of the world. The
guidelines recognize a pathway to PCD diagnosis with careful recognition of the phenotype
and access to genetic testing, making a diagnosis of PCD a reality for many geographic
locations without access to specialized testing, such as ciliary structural and functional
analysis or nNO testing. However, the guidelines also promote a network of accredited
centers with expertise in more specialized testing for those PCD clinical cases that are more
challenging. In this recognition, the ATS guidelines provide a platform for collaboration
with specialized PCD diagnostic centers throughout the world, including Europe. From
these perspectives, the ATS guidelines have a broad reach to inform the diagnosis of PCD
in many parts of the world.
5. PCD Foundation CRCN Overview
Over the last 15 years, the PCD Foundation has worked closely with clinicians and
researchers to uncover much of the PCD medical knowledge possessed today. Building
upon this success, the Foundation is establishing PCD centers of excellence across the US
and Canada. Most centers are tied to large academic medical institutions where patients
receive unified care from pulmonologists, otolaryngologists, cardiologists, neonatologists,
pathologists, and geneticists. Each center also has well-established ancillary supports
through nursing, social work, genetic counseling, and respiratory/physical therapy.
Through a detailed accreditation process, clinical centers are certified in nNO measurement with chemiluminescence devices, genetic testing with interpretation, and TEM
analysis of ciliary ultrastructure. All PCD diagnostic testing and interpretation is performed
using standardized protocols in close collaboration between the Foundation and expert
PCD physicians leading each center. Over 40 pediatric and adult locations are accredited
in the PCDF CRCN). (Figure 4). Each center closely collaborates on many aspects of PCD
clinical care with an annual academic conference where research products and clinical
innovations are presented.
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